Iovance Biotherapeutics (NASDAQ:IOVA) Trading Down 7.3% - Here's What Happened

Key Points

• Iovance Biotherapeutics shares fell 7.3% on Friday, dropping to as low as $3.88 amid lighter-than-average trading volume.
• Analysts have mixed views on the stock: several firms raised price targets or upgraded ratings, but the consensus remains Hold with an average target price of $8.43.
• The company’s latest earnings showed 44.9% revenue growth year over year and EPS that matched expectations, but revenue still missed estimates and profitability remains deeply negative.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report)'s share price fell 7.3% during mid-day trading on Friday . The stock traded as low as $3.88 and last traded at $3.9850. 7,668,251 shares were traded during mid-day trading, a decline of 49% from the average session volume of 15,027,618 shares. The stock had previously closed at $4.30.

Iovance Biotherapeutics News Summary

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Zacks Research raised its Q1 2028 EPS estimate for Iovance Biotherapeutics to ($0.08) from ($0.09), implying slightly better expected profitability. Iovance Biotherapeutics analyst estimate update
• Positive Sentiment: Analysts also increased estimates for Q2 2027 to ($0.11) from ($0.13) and Q1 2027 to ($0.13) from ($0.16), suggesting a somewhat improved earnings trajectory. Iovance Biotherapeutics analyst estimate update
• Positive Sentiment: A Zacks article said Iovance’s commercial momentum and expanding Amtagvi pipeline make it look better positioned than peer Agenus, which may reinforce a constructive view on the stock. Zacks article on Iovance versus Agenus
• Neutral Sentiment: Zacks Research trimmed some longer-dated estimates, including FY2026 to ($0.71) from ($0.69), Q3 2026 to ($0.17) from ($0.16), and Q4 2026 to ($0.17) from ($0.14), indicating the company is still expected to remain unprofitable for now. Iovance Biotherapeutics estimate revisions
• Neutral Sentiment: The company’s recent earnings backdrop remains mixed: revenue growth has been strong year over year, but the last reported quarter still missed revenue expectations, keeping investors focused on execution.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on IOVA shares. Barclays lifted their price target on shares of Iovance Biotherapeutics from $10.00 to $11.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 25th. Truist Financial upgraded shares of Iovance Biotherapeutics to a "hold" rating in a research note on Wednesday, March 25th. Wall Street Zen upgraded shares of Iovance Biotherapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, February 28th. Citizens Jmp upgraded shares of Iovance Biotherapeutics from a "market perform" rating to a "market outperform" rating and set a $5.00 price target on the stock in a research note on Tuesday, March 3rd. Finally, The Goldman Sachs Group restated a "sell" rating and issued a $2.00 target price on shares of Iovance Biotherapeutics in a research note on Thursday, February 5th. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $8.43.

Iovance Biotherapeutics Price Performance

The stock has a market capitalization of $1.79 billion, a P/E ratio of -4.24 and a beta of 0.69. The stock's fifty day moving average is $3.65 and its two-hundred day moving average is $3.11.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last issued its earnings results on Thursday, May 7th. The biotechnology company reported ($0.19) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.19). The firm had revenue of $71.43 million during the quarter, compared to analysts' expectations of $77.84 million. Iovance Biotherapeutics had a negative net margin of 123.92% and a negative return on equity of 50.17%. The firm's revenue for the quarter was up 44.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.36) earnings per share. Analysts expect that Iovance Biotherapeutics, Inc. will post -0.63 EPS for the current year.

Institutional Trading of Iovance Biotherapeutics

A number of large investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC boosted its holdings in Iovance Biotherapeutics by 55.1% during the first quarter. Janus Henderson Group PLC now owns 141,672 shares of the biotechnology company's stock worth $498,000 after buying an additional 50,331 shares in the last quarter. Arkadios Wealth Advisors acquired a new position in Iovance Biotherapeutics in the 1st quarter worth approximately $71,000. Royal Bank of Canada boosted its stake in Iovance Biotherapeutics by 2.7% in the 1st quarter. Royal Bank of Canada now owns 625,035 shares of the biotechnology company's stock worth $2,194,000 after purchasing an additional 16,576 shares during the period. The Manufacturers Life Insurance Company boosted its stake in Iovance Biotherapeutics by 57.9% in the 1st quarter. The Manufacturers Life Insurance Company now owns 365,471 shares of the biotechnology company's stock worth $1,283,000 after purchasing an additional 134,028 shares during the period. Finally, Corsair Capital Management L.P. boosted its stake in Iovance Biotherapeutics by 16.7% in the 1st quarter. Corsair Capital Management L.P. now owns 350,000 shares of the biotechnology company's stock worth $1,228,000 after purchasing an additional 50,000 shares during the period. 77.03% of the stock is currently owned by institutional investors.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company's lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance's pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance's TIL platform harnesses a patient's own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.